Metastatic Triple Negative Breast Cancer Clinical Trial
Official title:
Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
Verified date | December 2023 |
Source | The Methodist Hospital Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple negative breast cancer patients. The Phase Ib portion of the study is designed to investigate the combination at two dose levels of docetaxel (75 and 100 mg/m2) and 7 dose levels of L-NMMA (5, 7.5, 10, 12.5, 15, 17.5, and 20 mg/kg). The starting dose of L-NMMA will be 7.5 mg/kg. In the Phase II portion of the study, the starting dose will be the RP2D determined in the Phase Ib portion of the study.
Status | Completed |
Enrollment | 37 |
Est. completion date | January 2021 |
Est. primary completion date | January 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patient must meet all of the following criteria: • Female patients with pathologically determined advanced (progressive disease or refractory to 3 cycles of standard chemotherapy) or metastatic (any line) triple negative breast cancer (TNBC). TNBC is defined as: Estrogen receptor negative and progesterone receptor negative (<10% staining by immunohistochemistry [IHC]). Human epidermal growth factor receptor 2 (HER2) negative. HER2 negativity must be confirmed by one of the following: - Fluorescence in situ hybridization (FISH)-negative (FISH ratio <2), or - IHC 0-1+, or - IHC 2+ AND FISH-negative (FISH ratio <2). Eastern Cooperative Oncology Group performance status of = 2 - Age = 18 years - Laboratory values within the following ranges: - Hemoglobin =9.0 g/dL (transfusions permitted) - Absolute neutrophil count =1500/mm3 (1.5 x 109/L) - Platelet count =100,000/mm3 (100 x 109/L) - Total bilirubin <2 X upper limit of normal (ULN) - Creatinine (Cr) <2 X ULN and Cr clearance (CrCl) =30 by Cockcroft and Gault - Alanine transaminase (ALT) and aspartate transaminase (AST) <2 X ULN (if liver metastases are present then ALT and AST must be <5 X ULN) - Have adequate organ function (cardiac ejection fraction of = 45%) - Negative serum pregnancy test within 7 days of the administration of the first treatment dose for women of childbearing potential (WOCBP). For WOCBP, adequate contraception must be used throughout the study. - Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments. - Patient must be willing to undergo biopsies as required by the study protocol. Biopsies will be based on acceptable clinical risks as judged by investigator. Tissue from a previous biopsy will be accepted in the form of tissue slides. Exclusion Criteria: History of poorly controlled hypertension (defined as systolic blood pressure >150 mmHg at baseline) - Patients with metastatic disease who have received radiation therapy, chemotherapy, or non-cytotoxic investigational agents within 2 weeks of study treatment initiation. - Patients who received docetaxel at any line of treatment within the past 12 months - Evidence of New York Heart Association class III or greater cardiac disease - History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within the past 12 months - History of congenital QT prolongation - Absolute corrected QT interval of >480 msec in the presence of potassium >4.0 milliequivalent/L and magnesium >1.8 mg/dL - Any medical or psychiatric condition that would prevent informed consent or limit expected survival to less than 4 weeks - Symptomatic central nervous system metastases - Pregnant or nursing women - Hypersensitivity or intolerance to L-NMMA, docetaxel, amlodipine, pegfilgrastim, or their components - Use of amlodipine or another calcium channel blocker in the past 14 days - Alcoholism or hepatic disease with the exception of liver metastases - Severe renal insufficiency (CrCl <30 mL/min [Cockcroft and Gault]) - History of gastrointestinal bleeding, ulceration, or perforation - Concurrent use of potent cytochrome P450 (CYP)3A4 inhibitors - Concurrent use of potent CYP3A4 inducers - Concurrent use of medications that interact with nitrate/nitrites - Use of an investigational drug within 14 days preceding the first dose of study medication. - Concurrent use of any complementary or alternative medicines - Patients with > Grade 2 neuropathy - Inability to take aspirin |
Country | Name | City | State |
---|---|---|---|
United States | Houston Methodist Hospital | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The Methodist Hospital Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Area Under the Plasma Concentration Curve of the L-NMMA and Docetaxel Combination | Determine the area under the plasma concentration curve of the L-NMMA and docetaxel combination | 18 weeks | |
Other | Predictive Biomarkers | Determine potential predictive biomarkers including serum levels of nitrate/nitrite; serum levels of inflammatory biomarkers; angiogenesis-related biomarkers; and RPL39, MLF2, and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations in cell-free DNA | 18 weeks | |
Primary | Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients, Based on the Number of Dose Limiting Toxicities (DLTs) Per Dose Level. | The Phase Ib portion of the study is designed to investigate the combination at two dose levels of docetaxel (75 and 100 mg/m2) and 7 dose levels of L-NMMA (5, 7.5, 10, 12.5, 15, 17.5, and 20 mg/kg). The starting dose will be L-NMMA at 7.5 mg/kg and docetaxel at 75 mg/m2. As patients are accrued, a standard Bayesian model averaging continual reassessment method (CRM) approach will be used to determine the appropriate dosage. For a dose level to be chosen as the MTD, at least 4 patients must have received said dose without experiencing a significant number of DLTs based on the Bayesian Model Averaging Continual Reassessment Method. | DLTs assessment window is the duration required for completing one full cycle (through Day 21). | |
Primary | Clinical Benefit Rate | Primary Outcome Measure for Phase II: Determine the number of participants with complete response, partial response, or stable disease after 6 cycles of L-NMMA combined with taxane chemotherapy (docetaxel, paclitaxel, or nab-paclitaxel)/amlodipine, as assessed by the RECIST 1.1.
CR (complete response) = disappearance of all target lesions PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions SD (stable disease) = small changes that do not meet above criteria Treatment Failure: taken off the study because of adverse events before the first restaging scan after cycle 2 |
The approximate length of the study from Cycle 1, Day 1 will be approximately seven months (approximately four months of treatment plus three months of follow-up). | |
Primary | Asses the Maximum Tolerated Dose (MTD) of Docetaxel When Combined With L-NMMA/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients, Based on the Number of Dose Limiting Toxicities (DLTs) Per Dose Level. | The Phase Ib portion of the study is designed to investigate the combination at two dose levels of docetaxel (75 and 100 mg/m2) and 7 dose levels of L-NMMA (5, 7.5, 10, 12.5, 15, 17.5, and 20 mg/kg). The starting dose will be L-NMMA at 7.5 mg/kg and docetaxel at 75 mg/m2. As patients are accrued, a standard Bayesian model averaging continual reassessment method (CRM) approach will be used to determine the appropriate dosage. For a dose level to be chosen as the MTD, at least 4 patients must have received said dose without experiencing a significant number of DLTs based on the Bayesian Model Averaging Continual Reassessment Method. | DLTs assessment window is the duration required for completing one full cycle (through Day 21). | |
Secondary | Dose Limiting Toxicities (DLTs) and Other Adverse Events | Describe the DLTs and other adverse events associated with L-NMMA when combined with docetaxel/amlodipine, as assessed by the CTCAE v4.03 Any Grade = 3 Adverse Events (AE) unless there is clear alternative evidence that the AE was not caused by the study treatment. | The approximate length of the study from Cycle 1, Day 1 will be approximately seven months (approximately four months of treatment plus three months of follow-up). | |
Secondary | Recommended Phase 2 Dose (RP2D) of the L-NMMA and Docetaxel Combination | Determine the RP2D of the L-NMMA and docetaxel combination based on the occurrence of DLTs during Phase Ib portion of the study.
As patients are accrued, they will start with 7.5 mg/kg of L-NMMA and 75 mg/m2 of docetaxel and their DLTs will be assessed after completion of the first cycle. This will determine the next cohort dose, until at least 4 patients receive the dose with minimal DLTs that won't require dose reduction. |
The Dose Limiting Toxicities (DLT) assessment window is the duration required for completing one full cycle (through Day 21). | |
Secondary | Antitumor Activity | Assess the antitumor activity of L-NMMA when combined with taxane chemotherapy (docetaxel, paclitaxel, or nab-paclitaxel)/amlodipine, as assessed by the RECIST 1.1.
CR (complete response) = disappearance of all target lesions PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions SD (stable disease) = small changes that do not meet above criteria Treatment Failure: taken off the study because of adverse events before the first restaging scan after cycle 2 |
The approximate length of the study from Cycle 1, Day 1 will be approximately seven months (approximately four months of treatment plus three months of follow-up). | |
Secondary | Time to Maximum Plasma Concentration of L-NMMA and Docetaxel | Determine the time to maximum plasma concentration of the L-NMMA and docetaxel combination. | Blood samples will be collected predose (10-30 minutes before L-NMMA infusion) on Days 1, 2, and 5 of Cycle 1 and Days 1 and 5 of Cycle 2 for determination of L-NMMA plus docetaxel plasma PK. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02158507 -
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
|
N/A | |
Completed |
NCT02555657 -
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
|
Phase 3 | |
Completed |
NCT03121352 -
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03330847 -
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
|
Phase 2 | |
Completed |
NCT03256344 -
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
|
Phase 1 | |
Recruiting |
NCT04739670 -
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A | |
Completed |
NCT01238952 -
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT03577743 -
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT03411161 -
S 81694 Plus Paclitaxel in Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04149444 -
A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT05008510 -
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
|
Phase 2 | |
Completed |
NCT04111510 -
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT03055312 -
Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
|
Phase 3 | |
Recruiting |
NCT03709446 -
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
|
Phase 1/Phase 2 |